Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related condition, such as high blood pressure or type 2 diabetes
For the international research community, this limits direct access to the approved product
Highlights: Retatrutide targets GLP-1, GIP, and glucagon to reduce appetite, regulate fat storage, and manage blood sugar A trial showed a higher dose of Retatrutide produced 20% more weight loss over 48 weeks Common side effects include diarrhea, nausea, and vomiting , with at least one death reported Trusted Source Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial Go to source)
Several reasons may explain slower-than-expected results
What about the next generation of GLP-1 medications (triple agonists)
PCOS-specific nutrition guidance : We provide clear guidance on what to eat to maximize results and minimize side effects